Dermatomyositis Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Dermatomyositis companies are Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, others.
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dermatomyositis pipeline constitutes 10+ key companies continuously working towards developing 10+ Dermatomyositis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dermatomyositis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dermatomyositis Market.

The Dermatomyositis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Dermatomyositis Pipeline Outlook [https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Dermatomyositis Pipeline Report:

* Dermatomyositis Companies across the globe are diligently working toward developing novel Dermatomyositis treatment therapies with a considerable amount of success over the years.
* Dermatomyositis companies working in the treatment market are Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, others are developing therapies for the Dermatomyositis treatment.
* Emerging Dermatomyositis therapies such as EFG PH20, KZR-616, and others are expected to have a significant impact on the Dermatomyositis market in the coming years.
* In June 2024, Priovant Therapeutics, Inc announced results of a A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
* In June 2024, Galapagos announced results of a Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis
* In July 2024, CSL Behring announced a Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra Registered ) in Adults With Dermatomyositis (DM) - The RECLAIIM Study
* In June 2024, argenx announced results of a Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis
* In June 2024, AstraZeneca announced results of a Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Dermatomyositis Overview

Dermatomyositis is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. It is considered an autoimmune disorder, where the body's immune system mistakenly attacks its own tissues. The condition can affect both adults and children, with women being more frequently affected than men. The hallmark symptoms of dermatomyositis include muscle weakness, primarily in the shoulders, hips, and thighs, along with a violet-colored or dusky red rash on the face, eyelids, knuckles, elbows, knees, chest, and back.

Muscle weakness in dermatomyositis can lead to difficulty with everyday activities such as climbing stairs, rising from a seated position, or lifting objects. The skin rash often precedes the muscle weakness and can be exacerbated by sun exposure. Additional symptoms may include fatigue, difficulty swallowing, and lung problems. The exact cause of dermatomyositis is unknown, but genetic and environmental factors are believed to play a role.

Diagnosis involves a combination of clinical evaluation, blood tests for muscle enzymes, electromyography, muscle biopsy, and imaging studies. Treatment typically includes corticosteroids and immunosuppressive drugs to reduce inflammation and suppress the immune system. Physical therapy is also important to maintain muscle strength and function. Early diagnosis and treatment are crucial in managing symptoms and improving the quality of life for those affected by dermatomyositis.

Get a Free Sample PDF Report to know more about Dermatomyositis Pipeline Therapeutic Assessment- Dermatomyositis Drugs in Pipeline [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Dermatomyositis Route of Administration

Dermatomyositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.

Dermatomyositis Molecule Type

Dermatomyositis Products have been categorized under various Molecule types, such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Dermatomyositis Pipeline Therapeutics Assessment

* Dermatomyositis Assessment by Product Type
* Dermatomyositis By Stage and Product Type
* Dermatomyositis Assessment by Route of Administration
* Dermatomyositis By Stage and Route of Administration
* Dermatomyositis Assessment by Molecule Type
* Dermatomyositis by Stage and Molecule Type

DelveInsight's Dermatomyositis Report covers around 10+ products under different phases of clinical development like-

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Dermatomyositis product details are provided in the report. Download the Dermatomyositis pipeline report to learn more about the emerging Dermatomyositis therapies- Dermatomyositis Therapeutics Market [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Dermatomyositis Pipeline Analysis:

The Dermatomyositis pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Dermatomyositis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dermatomyositis Treatment.
* Dermatomyositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Dermatomyositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dermatomyositis market.

Download Sample PDF Report to know more about Dermatomyositis drugs and therapies- Dermatomyositis Clinical trials and FDA Approvals [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of Dermatomyositis Pipeline Drug Insight

* Coverage: Global
* Key Dermatomyositis Companies: Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, others.
* Key Dermatomyositis Therapies: EFG PH20, KZR-616, and others.
* Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies
* Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers

Request for Sample PDF Report for Dermatomyositis Pipeline Assessment and clinical trials - Dermatomyositis Drugs and Therapies [https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Dermatomyositis Report Introduction

2. Dermatomyositis Executive Summary

3. Dermatomyositis Overview

4. Dermatomyositis- Analytical Perspective In-depth Commercial Assessment

5. Dermatomyositis Pipeline Therapeutics

6. Dermatomyositis Late Stage Products (Phase II/III)

7. Dermatomyositis Mid Stage Products (Phase II)

8. Dermatomyositis Early Stage Products (Phase I)

9. Dermatomyositis Preclinical Stage Products

10. Dermatomyositis Therapeutics Assessment

11. Dermatomyositis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Dermatomyositis Companies

14. Dermatomyositis Key Products

15. Dermatomyositis Unmet Needs

16 . Dermatomyositis Market Drivers and Barriers

17. Dermatomyositis Future Perspectives and Conclusion

18. Dermatomyositis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dermatomyositis-pipeline-analysis-2024-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services



This release was published on openPR.